Curevac B.V. Stock Price, News & Analysis

CureVac announced promising preclinical results for its second-generation COVID-19 vaccine candidate, CV2CoV, developed in collaboration with GSK. The vaccine demonstrates high levels of antigen production and strong, fast-acting immune responses in rat models. Notably, CV2CoV elicited significant cross-neutralizing antibodies against variants of concern such as those from Denmark, the UK, and South Africa. The candidate is engineered for improved stability and efficacy, with clinical trials expected to commence in Q3 2021, aiming for broad protection against emerging strains.

CureVac N.V. (NASDAQ: CVAC) reported significant progress in its COVID-19 vaccine candidate CVnCoV, now in the final stage of clinical development with over 40,000 participants in a pivotal study across Europe and Latin America. The company anticipates interim efficacy data in Q2 2021. With a strong cash position of €1.32 billion as of December 31, 2020, and an additional $517.5 million raised in early 2021, CureVac is well-positioned for growth. Partnerships with Bayer, GSK, and the UK government aim to expedite vaccine development and expand production capacity to 1 billion doses by 2022.

CureVac N.V. (Nasdaq:CVAC) will announce its financial results and business updates for Q4 and the full year 2020 on April 15, 2021. A conference call and webcast will be held at 4:00 p.m. CET / 10:00 a.m. EST. Investors can access the webcast on the CureVac Investor Relations page. CureVac is focused on transformative medicines utilizing mRNA technology to create vaccines and therapies across various diseases. The company emphasizes its extensive experience in developing mRNA for medical applications.

CureVac N.V. (Nasdaq: CVAC) announced promising preclinical data for its COVID-19 vaccine candidate, CVnCoV, demonstrating protection against the SARS-CoV-2 variant B.1.351 (South African variant) in transgenic mice. The study showed that CVnCoV induced robust antibody responses, achieving full protection (100% survival) against both the original virus and the variant strain following a two-dose vaccination schedule. The vaccine effectively blocked viral replication in infected mice, underscoring its potential in combating emerging SARS-CoV-2 variants.

CureVac (Nasdaq:CVAC) is enhancing its late-stage clinical trials for its COVID-19 vaccine candidate, CVnCoV, in response to new variants. The pivotal HERALD Phase 2b/3 trial will now include select strains for a case-driven analysis. Additionally, a protocol amendment for the Phase 2a trial in older adults will add a secondary efficacy endpoint. CureVac aims for market authorization by Q2 2021 and anticipates data readouts from both trials in the same quarter.

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Production is set to begin in Q2 2021, aiming for up to 50 million doses by the end of 2021, and an additional 200 million doses in 2022 at Novartis' Kundl site in Austria. This collaboration enhances CureVac's European manufacturing network, expected to boost capacity significantly. The agreement is part of CureVac's ongoing development of mRNA-based vaccines initiated in January 2020, with prior successful clinical trials.

CureVac N.V. (NASDAQ:CVAC) announced its participation in two upcoming virtual investor conferences: the Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 am EST, and the Credit Suisse 2021 London Global Healthcare Conference on March 2, 2021, at 12:00 pm GMT / 7:00 am EST. Interested parties can find event details and access presentation materials on CureVac's Investor Relations page. The company, based in Tübingen, Germany, specializes in mRNA technology, with over 20 years of experience.

CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for its CVnCoV COVID-19 vaccine, currently in late-stage trials. The submission began with pre-clinical data that successfully passed technical validation. This process aims to streamline marketing authorization during the public health emergency. The HERALD trial is assessing CVnCoV in healthy adults across Europe and Latin America. CureVac emphasizes the potential of its mRNA technology in combating COVID-19 and highlights ongoing expansions in manufacturing capacity.

CureVac N.V. (NASDAQ:CVAC) is hosting a conference call on February 5, 2021, at 4:00 p.m. CET / 10:00 a.m. EST to discuss updates regarding its COVID-19 partnership. Interested participants can join via dial-in numbers or through a live webcast available on the CureVac website. The company is recognized for its innovative mRNA technology with over 20 years of expertise, focusing on developing treatments across various medical fields, including vaccines and cancer therapies. The call intends to outline future business strategies and updates on clinical developments.